Lv6
1608 积分 2024-03-21 加入
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
5天前
已完结
Efficacy and Safety of Ravulizumab in IgAN: Week 50 Results from a Phase 2 Randomized Controlled Trial
5天前
已关闭
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
5天前
已完结
Bupivacaine-Meloxicam Extended-Release Solution Compared with a Standard Periarticular Injection in Primary Total Knee Arthroplasty
11天前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
1个月前
已完结
SA83 {Maicplus}: An R Package to Support Analysis and Reporting of Matching Adjusted Indirect Treatment Comparisons (MAIC) for HTA Dossiers
1个月前
已完结
Comparative Effectiveness Without Head-to-Head Trials
1个月前
已完结
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
2个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
2个月前
已完结
皖公网安备34019202002308
